li001

The Phase 3 PEAK trial showed that adding the targeted drug bezuclastinib to sunitinib significantly improved outcomes for people with advanced gastrointestinal stromal tumors (GIST) who could not take imatinib or whose cancer had progressed on it. The combination cut the risk of cancer progression or death by half compared with sunitinib alone. Patients receiving […]

A Phase 3 trial, STELLAR-303, shows that combining zanzalintinib (XL092) with atezolizumab (Tecentriq) extends survival in patients with metastatic colorectal cancer compared with standard treatment regorafenib (Stivarga). Patients previously treated with chemotherapy and who were not MSI-high lived 10.9 months on the combination versus 9.4 months on regorafenib, with slower disease progression (3.7 vs. 2.0 months) and higher disease

Glioblastoma multiforme (GBM) is the most aggressive adult brain cancer, and treatment remains challenging. Standard therapy combines surgery, radiation, and temozolomide (TMZ) chemotherapy, sometimes with tumor-treating fields. A key factor is MGMT promoter methylation—tumors with methylation respond better to TMZ, improving survival from about 12 to nearly 15 months. Genetic profiling, including TERT promoter mutations, EGFR

GFH375, an experimental oral drug, is showing promising results for patients with advanced KRAS G12D–mutant pancreatic cancer, a mutation present in roughly 40% of pancreatic ductal adenocarcinomas. The early-phase trial involved daily 600 mg doses in patients who had already received multiple treatments. The therapy produced tumor shrinkage in 40.7% of patients, all partial responses, and